Challenge
Our client, a UK-based private equity company, was evaluating an investment in a full service global medical communications agency with a portfolio of blue-chip biopharma clients, and as part of its due diligence wanted to understand the technical and market risk associated with the target's product-based accounts.
Solution
For the assignment, Alacrita reviewed the top 80% of the company’s product accounts to identify prospective commercial risks to the company’s business. Our analysis confirmed that while two accounts faced significant commercial and/or technical risk, the portfolio as a whole was relatively balanced and robust with a low level of short-term risk.
Explore Our Due Diligence Services
Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate.
Healthcare Investor Support
Alacrita is frequently engaged by VCs and PE funds to provide objective valuations and due diligence assessments to support investment decisions, as well as early-stage expertise and operational support for NewCos., on an as needed basis.